Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions.

Imani Ghosh, Olivia Benson, Jorge H Hernandez-Felix, Frank I Lin, Karel Pacak, Jaydira Del Rivero

Abstract readReview

In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Imani GhoshDevelopmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.

Olivia BensonDevelopmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.

Jorge H Hernandez-FelixDevelopmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-8532-6509

Frank I LinMolecular Imaging Branch, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3539-1454

Karel PacakCenter for Adrenal Endocrine Tumors, AKESO, 155 00 Prague, Czech Republic.

Jaydira Del RiveroDevelopmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9710-4030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic or unresectable pheochromocytomas and paragangliomas (PPGLs) remain rare but clinically challenging neuroendocrine neoplasms with limited curative options. Traditionally managed with surgery, radionuclide therapy, or cytotoxic chemotherapy, systemic treatments have historically achieved disease stabilization, rather than durable remissions. In recent years, however, the therapeutic landscape has evolved substantially. Radiopharmaceuticals such as

Indexed as

chemotherapyHIF-2α inhibitorimmunotherapyparagangliomapheochromocytomaradiopharmaceuticalstyrosine kinase inhibitor

Identifiers

PMID41301064

DOI10.3390/cancers17223702

PMCPMC12650968

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.